Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1993792 citationsJournal Articlebronze Open Access

Authors

André M. Murad · Hospital das Clínicas da Universidade Federal de Minas Gerais

Flávia Ferretti Santiago · Hospital das Clínicas da Universidade Federal de Minas Gerais

Andy Petroianu · Hospital das Clínicas da Universidade Federal de Minas Gerais

Paulo Roberto Savassi Rocha · Hospital das Clínicas da Universidade Federal de Minas Gerais

Marco Antônio Gonçalves Rodrigues · Hospital das Clínicas da Universidade Federal de Minas Gerais

Marcelo Rausch · Hospital das Clínicas da Universidade Federal de Minas Gerais

Abstract

This regimen appears to prolong survival in patients with advanced gastric cancer, and the reduction of the methotrexate dose does not seem to compromise its efficacy.

Topics & Keywords

Gastric Cancer Management and Outcomes Gastrointestinal Tumor Research and Treatment Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 72, Issue 1, pp. 37-41

DOI: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p

Field-Weighted Citation Impact: 5.66